Allan Shaw says the biopharmaceutical industry had been heavily criticized by the media and the world going into the year before this episode.
“the biopharmaceutical industry was the favorite whipping boy of the media and of the world”
Person
Allan Shaw is a biopharmaceutical finance executive who appeared on the Business of Biotech podcast in an episode about a chief financial officer's view of success in the drug industry. He discussed industry reputation, hiring, spending discipline and funding.
Shaw said the industry went from discovery to available COVID-19 vaccines in less than a year, and that remote work lets biotech companies recruit beyond hubs such as Cambridge and San Diego. He said delaying development does not save money because overhead keeps being spent. He also predicted that capital markets will tighten and that investors will raise the bar on which biotech companies they fund.
1 episodes · 15 quoted claims
Allan Shaw says the biopharmaceutical industry had been heavily criticized by the media and the world going into the year before this episode.
“the biopharmaceutical industry was the favorite whipping boy of the media and of the world”
Allan Shaw says the industry went from discovery to available COVID-19 vaccines in less than a year.
“in less than a year, we've been able to go from discovery to actually having drugs available to vaccinate against COVID-19”
Allan Shaw says oncology companies shifted from chasing immuno-oncology (IO) to chasing precision oncology as the trend of the day.
“You saw that a couple of years back. Every oncology company wanted to suddenly be in IO. Now I think it's fashionable to be in precision oncology.”
Allan Shaw says that after COVID-19 showed remote work was possible, biotech companies can recruit talent beyond hubs such as Cambridge, San Diego, Carolina and Philadelphia.
“You're no longer stuck to the hubs of Cambridge or the hubs of San Diego or Carolina or Philadelphia, for that matter.”
Allan Shaw says there are anecdotal reports of very high employee turnover in the Boston-Cambridge biotech market, with people moving between nearby companies.
“certainly in the Boston, Cambridge, you know, there's a lot of anecdotal stories about people just the turnover, just being incredible people just crossing the street”
Allan Shaw says wealth creation for employees is associated with equity rather than cash pay, which he says covers overhead.
“if you want to create wealth and ultimately move the needle, it's good. Wealth creation is associated with the equity.”
Allan Shaw says delaying development does not save money because overhead continues to be spent, raising the cost of reaching success.
“But in fact, you're still burning overhead. So it's actually, you've actually incrementally increased the cost of success at the end of the day.”
Allan Shaw cites the amyloid plaque hypothesis in Alzheimer's disease as an example of people sticking to a hypothesis despite scientific evidence pointing elsewhere.
“not to beat up on Alzheimer's or the amyloid plaque hypothesis, but that's a classic example of people really sticking very doggedly at a hypothesis”
Allan Shaw says he helped take Syndax, a former company of his, public a couple of years before this episode.
“one of my former companies, Syndax, which I helped take public a couple of years ago”
Syndax went public with entinostat, an HDAC inhibitor in phase three with promise in immuno-oncology, as its single lead molecule.
“we did that with an HDAC, a Tinnostat, which was in phase three and had a lot of promise and IO, but it was one molecule.”
Allan Shaw says Syndax's entinostat program was later discontinued, and within six months the company brought in an antibody showing promise.
“the Tennis Stat program is no longer in development for a number of different reasons. But to the team's credit, you know, we within six months, we brought in an antibody that's showing some promise.”
Allan Shaw says Syndax now has a menin inhibitor that forms the fundamental basis of the company's investment thesis.
“They have an incredibly exciting menin inhibitor now. And that's really the fundamental basis of the company's investment thesis.”
Allan Shaw cites ordering phase three drug product materials while still in phase two as an example of costly premature spending.
“where you are in terms of ordering phase three drug product materials when you're still in phase two”
Allan Shaw says biotech valuations at the time could not be rationalized by most sell-side analysts, raising questions about market durability.
“valuations are not currently at a level that can be rationalized by most sell side analysts”
Allan Shaw predicts capital markets will tighten and investors will raise the bar on which biotech companies they fund.
“there's going to be some tightening and that the bars, they're going to raise the bar in terms of who they fund and who they don't fund.”